From patent infringement claims to underrepresentation of pregnant women in clinical data, each week we highlight five things to know in life sciences. … READ MORE >
life sciences
5 things to know in life sciences: Week of March 7, 2022
This week we highlight changes in drug exclusivity, international mRNA manufacturing expansion and more. … READ MORE >
5 things to know in life sciences: Week of Feb. 28, 2022
This week we highlight clinical holds on cell and gene therapies, clinical trials and patient experience, artificial intelligence and identifying bone fractures, and more. Each week we highlight five things you need to know about in the life sciences industry. Here’s the latest. … READ MORE >
5 things to know in life sciences: Week of Feb. 21, 2022
Each week we highlight five things you need to know about in the life sciences industry. Here’s the latest. … READ MORE >
5 things to know in life sciences: Week of Feb. 14, 2022
Each week we highlight five things you need to know about in the life sciences industry. Here’s the latest. … READ MORE >
5 things to know in life sciences: Week of Feb. 7, 2022
From regulatory challenges to a cartilage implant inspired by spiders, each week we highlight five things to know in the life sciences industry. … READ MORE >
Biopharma business outlook: Spring 2022
From approvals to investing, what’s on the horizon for middle market biopharma companies in 2022? … READ MORE >
The need for regulatory framework modernization: Spring 2022 medtech outlook
The number of novel medical devices brought to market continues to grow; keeping up with reviews will remain an ongoing challenge for the FDA. … READ MORE >
Macroeconomic drivers for life sciences: Spring 2022 outlook
For the life sciences ecosystem to continue to thrive, leaders must reevaluate their operating environment and plan for key drivers this year. … READ MORE >
Life sciences industry outlook: Spring 2022
Innovation and adaptation of life sciences in 2022 will be shaped by the major drivers of supply chain issues, human capital availability and capital markets. … READ MORE >